Cost of Revenue in USD of Ernexa Therapeutics Inc. from Q3 2022 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Ernexa Therapeutics Inc. quarterly/annual Cost of Revenue history and growth rate from Q3 2022 to Q4 2024.
  • Ernexa Therapeutics Inc. Cost of Revenue for the quarter ending December 31, 2024 was $0.000.
  • Ernexa Therapeutics Inc. Cost of Revenue for the twelve months ending December 31, 2024 was $96K.
  • Ernexa Therapeutics Inc. annual Cost of Revenue for 2024 was $96K, a 59.3% decline from 2023.
  • Ernexa Therapeutics Inc. annual Cost of Revenue for 2023 was $236K.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)

Ernexa Therapeutics Inc. Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $96K $0 Oct 1, 2024 Dec 31, 2024 10-K 2025-03-12
Q3 2024 -$60K -$180K -150% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $95K Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $61K +$11K +22% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q3 2023 $120K +$120K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q1 2023 $50K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13

Ernexa Therapeutics Inc. Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $96K -$140K -59.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-12
2023 $236K +$236K Jan 1, 2023 Dec 31, 2023 10-K 2025-03-12
2022 $0 Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.